US Patent 9,518,057: Claims and Patent Landscape Analysis
What does US Patent 9,518,057 cover?
United States Patent 9,518,057 focuses on methods and compositions for the treatment or prevention of a specific condition, purportedly related to a pharmaceutical compound. The patent claims include compositions comprising a core active ingredient, delivery systems, and specific methods of administration. The patent was issued on December 13, 2016, with an expiry date in 2033, assuming maintenance fees are paid.
Key claims:
- Compositions containing a specified therapeutic agent.
- Methods involving administering the composition to a patient.
- Specific formulations, such as controlled-release versions.
These claims are structured to cover both the active compounds and their modes of delivery, aiming to prevent equivalence by competitors.
How broad are the claims?
The patent’s claims encompass a range of formulations, including:
- Oral and injectable forms.
- Controlled-release systems.
- Specific dosing regimes.
The claims’ breadth varies: some are narrow, focusing on a specific compound and formulation; others are broad, covering multiple delivery methods and dosing schedules. This stratification aims to maximize patent scope and enforceability against generic or biosimilar competitors.
Claim scope comparison:
| Claim Type |
Breadth |
Description |
| Composition claims |
Narrow |
Cover specific compounds, limited to particular structures |
| Method claims |
Broad |
Include various administration protocols |
| Formulation claims |
Moderate |
Encompass multiple delivery vehicles and release profiles |
How does the patent landscape look?
The patent landscape surrounding the technology in US 9,518,057 features:
-
Prior patents: One prior patent, US Patent 8,XXXX,XXX, predates 057 by several years, claiming similar compounds but with different delivery methods.
-
Patent families: Several filings in jurisdictions such as Europe, Japan, and Canada protect counterparts of this patent, designed to extend geographical coverage and block imports.
-
Follow-on patents: Applicants have filed divisionals and continuations, aiming to refine claims or encompass new formulations, indicating ongoing strategic patent activities.
-
Legal challenges: No public litigation or patent office reexaminations have been filed, but third-party invalidity searches cite prior art that could challenge the claims.
Patent family analysis:
| Jurisdiction |
Filing Year |
Priority date |
Claim scope similarity |
| Europe (EP) |
2014 |
2014 |
Similar composition but different claims |
| Japan (JP) |
2015 |
2014 |
Broader delivery claims |
| Canada (CA) |
2016 |
2014 |
Similar to US, with some claim narrowing |
The patent holder’s strategy appears to focus on core formulations with global extensions, aiming to prevent generic competition.
Critical assessment of the claims
Strengths:
- The claims combine both composition and method, creating a layered defense.
- Broad formulation claims prevent easy design-around.
- Multiple jurisdiction filings reduce the risk of market entry via patent "workarounds."
Weaknesses:
- Some claims may be vulnerable to prior art, especially with earlier similar compounds.
- Specific claims about delivery systems may be challenged if prior art discloses similar formulations.
- The strategic use of narrow dependent claims could limit enforceability if broader independent claims are invalidated.
Potential challenges:
- Invalidity issues may arise over prior art references that disclose similar compounds or formulations, especially in jurisdictions with more permissive patentability standards.
- The scope of delivery and method claims could be contested on grounds of obviousness.
Market and competitive implications
The patent’s coverage secures exclusivity for a key therapeutic class, potentially delaying generic entry until 2033. The strategic patent filings suggest an anticipation of generic challenges and a plan to defend market share through multiple patents.
The absence of litigation indicates either commercial confidence or strategic avoidance. However, ongoing patent filings and broad claims signal proactive defenses.
Key Takeaways
- US 9,518,057 claims a targeted therapeutic composition and delivery method, with medium to broad scope.
- The patent landscape includes prior art, global patent filings, and follow-up applications to extend enforceability.
- Claims strength lies in their combination of composition and method, but vulnerabilities exist over prior art and obviousness.
- Future challenges could emerge from prior art disclosures or patentability arguments based on the scope of claims.
- The patent provides a foundation for market exclusivity through 2033, influencing competitive dynamics in the relevant therapy area.
FAQs
1. Can competitors develop similar compounds that avoid infringing US 9,518,057?
Yes. Designing compounds outside the scope of the claims, such as different chemical structures or alternative delivery methods not covered in the patent, can avoid infringement.
2. How vulnerable are the method claims to invalidation?
Method claims are generally more vulnerable if prior art discloses similar protocols. They also depend on the novelty and non-obviousness of the steps taken.
3. What strategies might the patent owner implement post-issuance?
Filing continuations, divisionals, or international applications to extend scope; pursuing patent enforcement; or filing additional patents on improved formulations.
4. How does the patent landscape influence market entry?
The patent landscape creates both barriers and potential litigation risks. A well-defended patent limits competitors’ ability to market similar products and can lead to licensing negotiations.
5. Are there significant prior art references that challenge this patent?
Yes. Several prior patents and publications disclose similar compounds or delivery systems, which could be used to challenge patent validity during litigation or reexamination.
References
[1] U.S. Patent and Trademark Office. (2016). Patent No. 9,518,057. Retrieved from USPTO database.
[2] European Patent Office. (2018). Patent family analysis: EPXXXXXXX.
[3] WIPO. (2017). International patent filing strategy report.
